Researchers found higher levels of a blood marker in former football players whose autopsies later confirmed advanced chronic traumatic encephalopathy, or CTE. The finding points toward a possible blood test for the brain disease, which doctors can currently confirm only after death.
The study, which JAMA published, examined blood from 21 former football players who donated their brains after death. The team, led by Boston University and Banner Health, included a researcher from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio.
What the blood samples showed
Autopsies identified CTE in 18 donors. Sixteen had advanced disease, and two had early-stage disease. The blood marker, a fragment of the protein tau known as eMTBR-tau, reached higher levels in the advanced group than in the early-stage group or in the three donors without CTE.
The five donors with both CTE and Alzheimer’s-related brain changes had the highest levels. The difference between advanced CTE and the other groups persisted after researchers excluded those five donors. The authors called for larger studies to determine how accurately the marker identifies CTE and whether it can distinguish CTE from other diseases.
A separate JAMA study found a similar pattern. Researchers analyzed blood plasma from 11 people with autopsy-confirmed CTE within a broader study of 229 participants. The marker helped distinguish advanced CTE from cognitively unimpaired controls. Results for the earliest stage were inconclusive.
Why early detection remains an open question
CTE is a degenerative brain disease associated with repeated head impacts. Researchers have documented memory problems, aggression, difficulty controlling impulses, and mood changes in people later found to have CTE. Some also experienced suicidal thoughts, though researchers have yet to establish whether CTE directly causes them.
One study estimated that at least one in four former NFL players who died between 2016 and 2021 had CTE. Doctors can confirm the disease only by examining brain tissue after death.
In July, Boston University researchers diagnosed former Dallas Cowboys defensive end Marshawn Kneeland with stage 1 CTE after his death, as The Dallas Express previously reported. Before his death, Kneeland had reportedly expressed suicidal thoughts, and soon afterward was found dead from an apparent self-inflicted gunshot wound.
A validated blood marker could help researchers identify candidates for treatment trials. Michael Alosco, co-senior author of the football player study and co-director of clinical research at Boston University’s CTE Center, said in an interview with WBUR, “If we can validate our findings and this holds up, it’s gonna really change the landscape of clinical research and clinical care.”